InvestLog
XTLB XTL Biopharmaceuticals Ltd. logo

XTLB XTL Biopharmaceuticals Ltd.

Healthcare
$2.51-1.18%ClosedMarket Cap: $5.9M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.82

P/S

13.87

EV/EBITDA

-6.48

DCF Value

$28.55

FCF Yield

-26.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.7%

Operating Margin

-481.6%

Net Margin

-227.7%

ROE

-26.8%

ROA

-12.0%

ROIC

-29.7%

Financials

View All
PeriodRevenueNet IncomeEPS
Q4 null$289.0K$-255.0K$—
FY null$451.0K$-1.0M$—
Q3 null$162.0K$-553.0K$—
Q2 null$0.00$-704.0K$—

Analyst Ratings

View All

Consensus

—

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

0 Strong Buy0 Buy0 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All
Segal Niv
SellMon Mar 23
Hillel Fain Osnatdirector
SellMon Mar 23
EDELMAN JOSEPH10 percent owner
SellWed Dec 03
EDELMAN JOSEPH10 percent owner
SellWed Dec 03
EDELMAN JOSEPH10 percent owner
SellWed Dec 03

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

IL

Exchange

—

Beta

0.71

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

Peers

AIM logoAIMCYCN logoCYCNENSC logoENSCKALA logoKALAKTTA logoKTTAPLRZ logoPLRZQNRX logoQNRXRADX logoRADXTCRT logoTCRTVYNE logoVYNE